Bristol-Myers Squibb Company (BMY) |
|
79.14 -0.1 (-0.13%)
|
11-28 16:00 |
|
Open: |
79.28 |
Pre. Close: |
79.24 |
|
High:
|
79.7 |
Low:
|
78.815 |
|
Volume:
|
6,269,371 |
Market Cap:
|
168,264(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 4:38:21 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 94.8 One year: 110.73 |
| Support: |
Support1: 75.65  Support2: 72.25 |
| Resistance: |
Resistance1: 81.16 Resistance2: 94.8 |
| Pivot: |
78.2 |
| Moving Average: |
MA(5): 79.06 MA(20): 78.14
MA(100): 73.31 MA(250): 71.57 |
| MACD: |
MACD(12,26): 1.3 Signal(9): 1.3 |
| Stochastic oscillator: |
%K(14,3): 69.8 %D(3): 68.4 |
| RSI: |
RSI(14): 64.3 |
| 52-week: |
High: 81.16 Low: 56.11 |
| Average Vol(K): |
3-Month: 9,553 (K) 10-Days: 8,136 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BMY ] has closed below upper band by 33.4%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
79.79 - 80.21 |
80.21 - 80.57 |
|
Low:
|
77.84 - 78.32 |
78.32 - 78.73 |
|
Close:
|
78.35 - 79.17 |
79.17 - 79.86 |
|
Company Description |
|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
Headline News |
Mon, 28 Nov 2022
IVE, BMY, COP, NEE: Large Inflows Detected at ETF - Nasdaq
Fri, 25 Nov 2022
Bristol-Myers Squibb (NYSE:BMY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Thu, 24 Nov 2022
BMY: 2 Stocks to Buy if You Want Passive Income in 2023 - StockNews.com
Wed, 23 Nov 2022
BMY: 3 Stocks to Buy This Month if You Haven't Already - StockNews.com
Fri, 18 Nov 2022
Noteworthy Friday Option Activity: PRU, DE, BMY - Nasdaq
Wed, 16 Nov 2022
Bristol-Myers Squibb Company (BMY) Presents at 4th Annual Wolfe Research Healthcare Conference (Transcript) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
2,130 (M) |
| Shares Float |
2,120 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
79.3 (%) |
|
Shares Short
|
24,770 (K) |
|
Shares Short P.Month
|
24,180 (K) |
Stock Financials |
|
EPS
|
3.06 |
|
EPS Est Next Qtl
|
0.79 |
|
EPS Est This Year
|
3 |
|
EPS Est Next Year
|
3.23 |
|
Book Value (p.s.)
|
15.38 |
|
Profit Margin (%)
|
14.2 |
|
Operating Margin (%)
|
21.9 |
|
Return on Assets (ttm)
|
6.1 |
|
Return on Equity (ttm)
|
19.1 |
|
Qtrly Rev. Growth
|
-3.5 |
|
Gross Profit (p.s.)
|
17.39 |
|
Sales Per Share
|
21.94 |
|
EBITDA (p.s.)
|
9.73 |
|
Qtrly Earnings Growth
|
8.6 |
|
Operating Cash Flow
|
13,820 (M) |
|
Levered Free Cash Flow
|
13,970 (M) |
Stock Valuations |
|
PE Ratio
|
25.77 |
|
PEG Ratio
|
2.4 |
|
Price to Book value
|
5.14 |
|
Price to Sales
|
3.6 |
|
Price to Cash Flow
|
12.19 |
Stock Dividends |
|
Dividend
|
0.54 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.6% |
|
Dividend Pay Date
|
2022-01-31 |
|
Ex-Dividend Date
|
2022-01-05 |
|
Your Ad Here
|
|
